Opipramol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Opipramol
Accession Number
DB12930
Type
Small Molecule
Groups
Investigational
Description

Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
D23ZXO613C
CAS number
315-72-0
Weight
Average: 363.505
Monoisotopic: 363.231062566
Chemical Formula
C23H29N3O
InChI Key
YNZFUWZUGRBMHL-UHFFFAOYSA-N
InChI
InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
IUPAC Name
2-[4-(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)piperazin-1-yl]ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Opipramol can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineOpipramol may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Opipramol can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineOpipramol may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Opipramol can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineOpipramol may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineOpipramol may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Opipramol.Experimental
AcenocoumarolOpipramol may increase the anticoagulant activities of Acenocoumarol.Approved
AgmatineOpipramol may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Opipramol can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Opipramol can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Opipramol.Approved
AmobarbitalThe metabolism of Opipramol can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineOpipramol may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Opipramol can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Opipramol can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Opipramol can be increased when it is combined with Apixaban.Approved
ApomorphineOpipramol may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineOpipramol may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Opipramol can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Opipramol is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Opipramol can be increased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Opipramol can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Opipramol can be increased when it is combined with Atazanavir.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Opipramol can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Opipramol can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Opipramol can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Opipramol can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Opipramol.Withdrawn
BenzamidineThe serum concentration of Opipramol can be increased when it is combined with Benzamidine.Experimental
BenzphetamineOpipramol may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
BethanidineOpipramol may decrease the antihypertensive activities of Bethanidine.Approved
BivalirudinThe serum concentration of Opipramol can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Opipramol can be increased when it is combined with Boceprevir.Approved, Withdrawn
BrimonidineOpipramol may decrease the antihypertensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Opipramol.Experimental
BromocriptineOpipramol may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Opipramol can be decreased when combined with Bupropion.Approved
CamostatThe serum concentration of Opipramol can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Opipramol can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Opipramol can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Opipramol can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Opipramol can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Opipramol.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Opipramol is combined with Celiprolol.Approved, Investigational
ChlorphentermineOpipramol may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
CholesterolThe serum concentration of Opipramol can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Opipramol can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Opipramol can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Opipramol can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Opipramol can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Opipramol can be increased when it is combined with Cinacalcet.Approved
CirazolineOpipramol may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Opipramol is combined with Citalopram.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClonidineOpipramol may decrease the antihypertensive activities of Clonidine.Approved
ClorindioneOpipramol may increase the anticoagulant activities of Clorindione.Experimental
Dabigatran etexilateThe serum concentration of Opipramol can be increased when it is combined with Dabigatran etexilate.Approved
DarexabanThe serum concentration of Opipramol can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Opipramol can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Opipramol can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Opipramol can be increased when it is combined with Delapril.Experimental
DesmopressinThe risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.Approved
DexmedetomidineOpipramol may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Opipramol.Approved
DextroamphetamineOpipramol may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolOpipramol may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionOpipramol may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineOpipramol may decrease the antihypertensive activities of Dihydroergotamine.Approved
DiphenadioneOpipramol may increase the anticoagulant activities of Diphenadione.Experimental
DipivefrinOpipramol may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Opipramol is combined with Dobutamine.Approved
DroxidopaOpipramol may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Opipramol.Approved
EcabetThe serum concentration of Opipramol can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Opipramol can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Opipramol can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Opipramol can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Opipramol can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Opipramol can be increased when it is combined with Enalkiren.Experimental
EphedraOpipramol may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Opipramol can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineOpipramol may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgotamineOpipramol may decrease the antihypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Opipramol is combined with Escitalopram.Approved, Investigational
Ethyl biscoumacetateOpipramol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateOpipramol may decrease the antihypertensive activities of Etomidate.Approved
FaldaprevirThe serum concentration of Opipramol can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Fenoterol.Approved, Investigational
FluindioneOpipramol may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Opipramol.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Opipramol.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Opipramol can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Opipramol can be increased when it is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Opipramol.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Opipramol can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Opipramol can be increased when it is combined with Geldanamycin.Experimental, Investigational
GepefrineOpipramol may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Opipramol can be increased when it is combined with GM6001.Experimental
GuanabenzOpipramol may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineOpipramol may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HarmalineHarmaline may increase the serotonergic activities of Opipramol.Experimental
HexobarbitalThe metabolism of Opipramol can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Opipramol.Experimental
HydroxyamphetamineOpipramol may increase the stimulatory activities of Hydroxyamphetamine.Approved
IdraparinuxThe serum concentration of Opipramol can be increased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Opipramol can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Indacaterol.Approved
IndinavirThe serum concentration of Opipramol can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Opipramol.Approved, Investigational
Iofetamine I-123Opipramol may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Opipramol.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Opipramol.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Opipramol.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Opipramol is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Opipramol can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoprenalineThe risk or severity of adverse effects can be increased when Opipramol is combined with Isoprenaline.Approved
IxazomibThe serum concentration of Opipramol can be increased when it is combined with Ixazomib.Approved
LepirudinThe serum concentration of Opipramol can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Opipramol can be increased when it is combined with Letaxaban.Investigational
LevonordefrinOpipramol may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Opipramol is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Opipramol.Approved
LinagliptinThe serum concentration of Opipramol can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Opipramol.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Opipramol.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Opipramol.Approved
LisdexamfetamineOpipramol may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Opipramol can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Opipramol.Approved
LofexidineOpipramol may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Opipramol can be increased when it is combined with Lopinavir.Approved
MebanazineMebanazine may increase the serotonergic activities of Opipramol.Withdrawn
MelagatranThe serum concentration of Opipramol can be increased when it is combined with Melagatran.Experimental
MephedroneOpipramol may increase the stimulatory activities of Mephedrone.Investigational
MephentermineOpipramol may increase the vasopressor activities of Mephentermine.Approved
MetaraminolOpipramol may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethamphetamineOpipramol may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Opipramol can be increased when combined with Methohexital.Approved
MethoxamineOpipramol may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyphenamineOpipramol may increase the stimulatory activities of Methoxyphenamine.Experimental
Methylene blueOpipramol may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol.Approved, Investigational
MethylphenobarbitalThe metabolism of Opipramol can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Opipramol.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Opipramol.Approved
MidodrineOpipramol may increase the vasopressor activities of Midodrine.Approved
MidomafetamineOpipramol may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MinaprineMinaprine may increase the serotonergic activities of Opipramol.Approved
MMDAOpipramol may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Opipramol.Approved
MoexiprilThe serum concentration of Opipramol can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Opipramol.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Opipramol can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Opipramol can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineOpipramol may decrease the antihypertensive activities of Naphazoline.Approved
NelfinavirThe serum concentration of Opipramol can be increased when it is combined with Nelfinavir.Approved
NialamideNialamide may increase the serotonergic activities of Opipramol.Withdrawn
NicorandilOpipramol may increase the hypotensive activities of Nicorandil.Approved, Investigational
NitroaspirinThe serum concentration of Opipramol can be increased when it is combined with Nitroaspirin.Investigational
NorepinephrineOpipramol may decrease the antihypertensive activities of Norepinephrine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Opipramol.Withdrawn
OlodaterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Opipramol can be increased when it is combined with Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Opipramol is combined with Orciprenaline.Approved
OtamixabanThe serum concentration of Opipramol can be increased when it is combined with Otamixaban.Investigational
OxymetazolineOpipramol may decrease the antihypertensive activities of Oxymetazoline.Approved
PaliperidoneOpipramol may decrease the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the serotonergic activities of Opipramol.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Opipramol.Approved, Investigational
PentobarbitalThe metabolism of Opipramol can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideOpipramol may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Opipramol can be increased when it is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Opipramol.Approved
PhenindioneOpipramol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Opipramol.Withdrawn
PhenobarbitalThe metabolism of Opipramol can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Opipramol.Withdrawn
PhenprocoumonOpipramol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineOpipramol may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineOpipramol may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Opipramol is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Opipramol can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Opipramol.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Opipramol.Withdrawn
PrimidoneThe metabolism of Opipramol can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Opipramol can be increased when it is combined with Prinomastat.Investigational
ProcarbazineProcarbazine may increase the serotonergic activities of Opipramol.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Procaterol.Approved, Investigational
PseudoephedrineOpipramol may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Opipramol can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineOpipramol may increase the QTc-prolonging activities of Quinidine.Approved
RacecadotrilThe serum concentration of Opipramol can be increased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Opipramol can be increased when it is combined with Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Opipramol.Approved
RemikirenThe serum concentration of Opipramol can be increased when it is combined with Remikiren.Approved
RisperidoneOpipramol may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronOpipramol may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Opipramol is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Opipramol can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Opipramol can be increased when it is combined with Rivaroxaban.Approved
RopiniroleOpipramol may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
S-3304The serum concentration of Opipramol can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Opipramol.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Opipramol is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Opipramol can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Opipramol can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Opipramol can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Opipramol.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Opipramol.Approved
SimeprevirThe serum concentration of Opipramol can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Opipramol can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Opipramol can be increased when it is combined with Sivelestat.Investigational
Sodium phosphateThe risk or severity of adverse effects can be increased when Opipramol is combined with Sodium phosphate.Approved
SpiraprilThe serum concentration of Opipramol can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Opipramol can be increased when combined with St. John's Wort.Investigational, Nutraceutical
TelaprevirThe serum concentration of Opipramol can be increased when it is combined with Telaprevir.Approved, Withdrawn
TemocaprilThe serum concentration of Opipramol can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Opipramol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Opipramol is combined with Terbutaline.Approved
ThiamylalThe metabolism of Opipramol can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Opipramol can be increased when combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Opipramol can be increased when it is combined with Thiorphan.Experimental
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Opipramol.Approved
TioclomarolOpipramol may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Opipramol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineOpipramol may decrease the antihypertensive activities of Tizanidine.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Opipramol.Approved
TramadolOpipramol may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Opipramol can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Opipramol.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Opipramol.Approved
UbenimexThe serum concentration of Opipramol can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Opipramol can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Opipramol can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Opipramol.Approved
VilanterolThe risk or severity of adverse effects can be increased when Opipramol is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Opipramol can be increased when it is combined with Vildagliptin.Approved, Investigational
WarfarinOpipramol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Opipramol can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineOpipramol may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Opipramol.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Opipramol can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZofenoprilThe serum concentration of Opipramol can be increased when it is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9417
PubChem Substance
347829075
ChemSpider
9046
BindingDB
50170636
ChEBI
94614
ChEMBL
CHEMBL370753
PharmGKB
PA144614922
ATC Codes
N06AA05 — Opipramol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentDrug Abuse1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP3.13ALOGPS
logP3.24ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)7.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.06 m3·mol-1ChemAxon
Polarizability42.65 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / N-alkylpiperazines / Azepines / Benzenoids / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / N-alkylpiperazine / 1,4-diazinane / Piperazine / Benzenoid / Tertiary aliphatic amine / Tertiary amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:22 / Updated on December 01, 2017 16:35